Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction

Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome

Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151

T cell exhaustion

Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062

Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing

Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775

Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer

Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397

Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker

Heagerty, P. J., Lumley, T., & PEPE, M. S. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00337.x · Cited by 2,870

The polycomb group protein EZH2 is involved in progression of prostate cancer

Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717

The Polycomb group protein EZH2 directly controls DNA methylation

Viré, E., Brenner, C., Deplus, R., Blanchon, L., Fraga, M., Didelot, C., Morey, L., Van Eynde, A., Bernard, D., Vanderwinden, J.-M., et al. (2006) · Nature · doi:10.1038/nature04431 · Cited by 2,204

Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis

Chang, C.-H., Curtis, J. D., Maggi, L. B., Faubert, B., Villarino, A. V., O’Sullivan, D., Huang, S. C.-C., van der Windt, G. J. W., Blagih, J., Qiu, J., et al. (2013) · Cell · doi:10.1016/j.cell.2013.05.016 · Cited by 2,204

Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer

Pagès, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., Mlecnik, B., Kirilovsky, A., Nilsson, M., Damotte, D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051424 · Cited by 2,135

Non-coding RNAs in CD8 T cell biology

Wells, A. C., Pobezinskaya, E. L., & Pobezinsky, L. A. (2020) · Molecular Immunology · doi:10.1016/j.molimm.2020.01.023 · Cited by 31

Metabolites in the Tumor Microenvironment Reprogram Functions of Immune Effector Cells Through Epigenetic Modifications

Li, Y., Wu, Y., & Hu, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.641883 · Cited by 31

Polycomb Directed Cell Fate Decisions in Development and Cancer

German, B., & Ellis, L. (2022) · Epigenomes · doi:10.3390/epigenomes6030028 · Cited by 34

Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies

Serganova, I. S., Chakraborty, S., Yamshon, S., Isshiki, Y., Bucktrout, R., Melnick, A. M., Béguelin, W., & Zappasodi, R. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.805195 · Cited by 30

Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic viruses

Yan, J., Chen, Y., Patel, A. J., Warda, S., Lee, C. J., Nixon, B. G., Wong, E. W. P., Miranda-Román, M. A., Yang, N., Wang, Y., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci153437 · Cited by 30

Recent progress in the immunotherapy of hepatocellular carcinoma: Non-coding RNA-based immunotherapy may improve the outcome

Afra, F., Mahboobipour, A. A., Farid, A. S., & Ala, M. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115104 · Cited by 30

Metabolism of T Lymphocytes in Health and Disease

Gaber, T., Chen, Y., Krauß, P.-L., & Buttgereit, F. (2018) · International review of cytology · doi:10.1016/bs.ircmb.2018.06.002 · Cited by 32

The Complex Role of EZH2 in the Tumor Microenvironment: Opportunities and Challenges for Immunotherapy Combinations

Qiu, J., Sharma, S., Rollins, R. A., & Paul, T. A. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0072 · Cited by 30

mTOR Signaling Promotes Rapid m6A mRNA Methylation to Regulate NK-Cell Activation and Effector Functions

Meng, M., Zhong, Z., Song, L., Zhang, Z., Yin, X., Xie, X., Tian, L., Wu, W., Yang, Y., Deng, Y., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0339 · Cited by 28

Polycomb Repressive Complex 2: Emerging Roles in the Central Nervous System

Liu, P., Xu, Y., Teng, Z., & Liu, C. (2017) · The Neuroscientist · doi:10.1177/1073858417747839 · Cited by 29

Tumor hypermetabolism confers resistance to immunotherapy

Liu, A. J., & Curran, M. A. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.009 · Cited by 29

Increased Expression of EZH2 Is Mediated by Higher Glycolysis and mTORC1 Activation in Lupus CD4+ T Cells

Zheng, X., Tsou, P., & Sawalha, A. H. (2020) · Immunometabolism · doi:10.20900/immunometab20200013 · Cited by 27

Notch Pathway: A Journey from Notching Phenotypes to Cancer Immunotherapy

Monticone, G., & Miele, L. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-55031-8_13 · Cited by 28

The role of tumor metabolism in modulating T-Cell activity and in optimizing immunotherapy

Ganjoo, S., Gupta, P., Corbali, H. I., Nanez, S., Riad, T. S., Duong, L. K., Barsoumian, H. B., Masrorpour, F., Jiang, H., Welsh, J. W., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1172931 · Cited by 32

Tumor cell metabolic reprogramming and hypoxic immunosuppression: driving carcinogenesis to metastatic colonization

Katopodi, T., Petanidis, S., Anestakis, D., Charalampidis, C., Chatziprodromidou, I. P., Floros, G., Eskitzis, P., Zarogoulidis, P., Koulouris, C., Sevva, C. D., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1325360 · Cited by 28

The Fate Choice Between Effector and Memory T Cell Lineages: Asymmetry, Signal Integration, and Feedback to Create Bistability

Backer, R. A., Hombrink, P., Helbig, C., & Amsen, D. (2018) · Advances in immunology · doi:10.1016/bs.ai.2017.12.003 · Cited by 27

A hypoxia risk signature for the tumor immune microenvironment evaluation and prognosis prediction in acute myeloid leukemia

Jiang, F., Mao, Y., Lu, B., Zhou, G., & Wang, J. (2021) · Scientific Reports · doi:10.1038/s41598-021-94128-1 · Cited by 27

IL-7 signaling imparts polyfunctionality and stemness potential to CD4+ T cells

Ding, Z., Liu, C., Cao, Y., Habtetsion, T. G., Kuczma, M., Pi, W., Kong, H., Çaçan, E., Greer, S. F., Cui, Y. R., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1171445 · Cited by 28

EZH2 promotes neoplastic transformation through VAV interaction-dependent extranuclear mechanisms

Venkatesan, N., Wong, J. F., Tan, K. P., Chung, H. H., Yau, Y. H., Cukuroglu, E., Allahverdi, A., Nordenskiöld, L., Göke, J., Shochat, S. G., et al. (2017) · Oncogene · doi:10.1038/onc.2017.309 · Cited by 29

Recent Insight on Regulations of FBXW7 and Its Role in Immunotherapy

Xing, L., Xu, L., Zhang, Y., Che, Y., Wang, M., Shao, Y., Qiu, D., Yu, H., Zhao, F. H., & Zhang, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.925041 · Cited by 25

Molecular insights and clinical implications for the tumor suppressor role of SCFFBXW7 E3 ubiquitin ligase

Qi, Y., Rezaeian, A.-H., Wang, J., Huang, D., Chen, H., Inuzuka, H., & Wei, W. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189140 · Cited by 27

miR-155 Overexpression in OT-1 CD8+ T Cells Improves Anti-Tumor Activity against Low-Affinity Tumor Antigen

Monnot, G., Martínez-Usatorre, A., Lanitis, E., Lopes, S. F., Cheng, W.-C., Ho, P., Irving, M. B., Coukos, G., Donda, A., & Romero, P. J. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.12.008 · Cited by 26

Epigenetic Regulation of Cancer Immune Cells

Patino, D. M. A., Radhakrishnan, V., Suvilesh, K. N., Manjunath, Y., Li, G., Kimchi, E. T., Staveley-O’Carroll, K. F., Warren, W. C., Kaifi, J. T., & Mitchem, J. B. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.022 · Cited by 26

Importance of T, NK, CAR T and CAR NK Cell Metabolic Fitness for Effective Anti-Cancer Therapy: A Continuous Learning Process Allowing the Optimization of T, NK and CAR-Based Anti-Cancer Therapies

Krug, A., Martinez-Turtos, A., & Verhoeyen, E. (2021) · Cancers · doi:10.3390/cancers14010183 · Cited by 28

Filling the Tank: Keeping Antitumor T Cells Metabolically Fit for the Long Haul

Delgoffe, G. M. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0244 · Cited by 26

Metabolic checkpoints and novel approaches for immunotherapy against cancer

Li, Y., Tang, J., Jiang, J., & Chen, Z. (2021) · International Journal of Cancer · doi:10.1002/ijc.33781 · Cited by 29

MicroRNA-Mediated Metabolic Shaping of the Tumor Microenvironment

Virga, F., Quirico, L., Cucinelli, S., Mazzone, M., Taverna, D., & Orso, F. (2021) · Cancers · doi:10.3390/cancers13010127 · Cited by 25

Inhibition of the Histone Methyltransferase EZH2 Enhances Protumor Monocyte Recruitment in Human Mesothelioma Spheroids

Mola, S., Pinton, G., Erreni, M., Corazzari, M., Andrea, M. D., Grolla, A. A., Martini, V., Moro, L., & Porta, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094391 · Cited by 27

Bypassing anti-PD-(L)1 therapy: Mechanisms and management strategies

Mortezaee, K., Majidpoor, J., Najafi, S., & Tasa, D. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114150 · Cited by 26

Use of complement binding assays to assess the efficacy of antibody mediated rejection therapy and prediction of graft survival in kidney transplantation

Ramón, D. S., Huang, Y., Zhao, L., Rendulic, T., Park, J. M., Sung, R. S., & Samaniego, M. (2016) · Human Immunology · doi:10.1016/j.humimm.2016.11.009 · Cited by 24

The functions of EZH2 in immune cells: Principles for novel immunotherapies

Shao, F.-F., Chen, B.-J., & Wu, G. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.1ru0520-311r · Cited by 23

Primary Aldosteronism: Metabolic Reprogramming and the Pathogenesis of Aldosterone-Producing Adenomas

Gong, S., Tetti, M., Reincke, M., & Williams, T. A. (2021) · Cancers · doi:10.3390/cancers13153716 · Cited by 24

The metabolic addiction of cancer stem cells

Sahoo, O. S., Pethusamy, K., Srivastava, T. P., Talukdar, J., Alqahtani, M. S., Abbas, M. A. E., Dhar, R., & Karmakar, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.955892 · Cited by 26

The role of histone methylase and demethylase in antitumor immunity: A new direction for immunotherapy

Zhang, Y., Chen, J., Liu, H., Mi, R., Huang, R., Li, X., Fei, F., Xie, X., & Ding, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1099892 · Cited by 25

Nanogap-based all-electronic DNA sequencing devices using MoS 2 monolayers

Perez, A., Amorim, R. G., Villegas, C. E. P., & Rocha, A. R. (2020) · Physical Chemistry Chemical Physics · doi:10.1039/d0cp04138f · Cited by 23

Elucidating tumour‐associated microglia/macrophage diversity along glioblastoma progression and under ACOD1 deficiency

Pires‐Afonso, Y., Muller, A., Grzyb, K., Oudin, A., Yabo, Y. A., Sousa, C., Scafidi, A., Poli, A., Cosma, A., Halder, R., et al. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13287 · Cited by 25

Metabolic reprogramming by miRNAs in the tumor microenvironment: Focused on immunometabolism

Alshahrani, S. H., Ibrahim, Y. S., Jalil, A. T., Altoum, A. A., Achmad, H., Zabibah, R. S., Gabr, G. A., Ramírez‐Coronel, A. A., Alameri, A. A., Qasim, Q. A., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1042196 · Cited by 24

Epigenetic Regulation of Stromal and Immune Cells and Therapeutic Targets in the Tumor Microenvironment

Liu, K., Li, Y., Shen, M., Xu, W., Wu, S., Yang, X., Zhang, B., & Lin, N. (2025) · Biomolecules · doi:10.3390/biom15010071 · Cited by 23

Posttranscriptional Regulation of RhBRC1 (Rosa hybrida BRANCHED1) in Response to Sugars is Mediated via its Own 3′ Untranslated Region, with a Potential Role of RhPUF4 (Pumilio RNA-Binding Protein Family)

Wang, M., Ogé, L., Voisine, L., Pérez-Garcia, M.-D., Jeauffre, J., Oyant, L. H., Grappin, P., Hamama, L., & Sakr, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153808 · Cited by 24

Nicotinamide Inhibits T Cell Exhaustion and Increases Differentiation of CD8 Effector T Cells

Alavi, S., Emran, A. A., Tseng, H., Tiffen, J. C., McGuire, H. M., & Hersey, P. (2022) · Cancers · doi:10.3390/cancers14020323 · Cited by 22

The TGFα-EGFR-Akt signaling axis plays a role in enhancing proinflammatory chemokines in triple-negative breast cancer cells

Ignacio, R. M. C., Gibbs, C. R., Lee, E.-S., & Son, D. (2018) · Oncotarget · doi:10.18632/oncotarget.25389 · Cited by 21

Reprogramming T-Cell Metabolism for Better Anti-Tumor Immunity

Ping, Y., Shen, C., Huang, B., & Zhang, Y. (2022) · Cells · doi:10.3390/cells11193103 · Cited by 22

The tumor microenvironment disarms CD8+ T lymphocyte function via a miR-26a-EZH2 axis

Long, H., Xiang, T., Luo, J., Li, F., Lin, R., Liu, S.-Q., Jiang, S., Hu, C., Chen, G., Wong, E., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1245267 · Cited by 21

Metabolic manipulation of the tumour immune microenvironment

Wan, M., Ding, Y., Li, Z., Wang, X., & Xu, M. (2021) · Immunology · doi:10.1111/imm.13444 · Cited by 21

The Role of FBXW7 in Gynecologic Malignancies

Fiore, R. D., Suleiman, S., Drago‐Ferrante, R., Subbannayya, Y., Suleiman, S., Vasileva‐Slaveva, M., Yordanov, A. D., Pentimalli, F., Giordano, A., & Calleja‐Agius, J. (2023) · Cells · doi:10.3390/cells12101415 · Cited by 21

Targeting KDM2A Enhances T-cell Infiltration in NSD1-Deficient Head and Neck Squamous Cell Carcinoma

Chen, C., Shin, J. H., Fang, Z., Brennan, K., Horowitz, N. B., Pfaff, K. L., Welsh, E. L., Rodig, S. J., Gevaert, O., Gozani, O., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3114 · Cited by 20

Distinctive profiles of tumor-infiltrating immune cells and association with intensity of infiltration in colorectal cancer

Wu, Y., Yuan, L., Lu, Q., Xu, H., & He, X. (2018) · Oncology Letters · doi:10.3892/ol.2018.7771 · Cited by 20

Therapeutic potential of enhancer of zeste homolog 2 in autoimmune diseases

Yang, Y., Shen, H., Cao, F., Xie, L., Zhu, G.-L., Sam, N. B., Wang, D., & Pan, H. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1696309 · Cited by 20

Myeloid Fbxw7 Prevents Pulmonary Fibrosis by Suppressing TGF-β Production

He, J., Du, Y. J., Li, G., Xiao, P., Sun, X., Song, W., Lai, L., Meng, X., Zhang, J., & Wang, Q. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.760138 · Cited by 20

Salmonella cancer therapy metabolically disrupts tumours at the collateral cost of T cell immunity

Copland, A., Mackie, G. M., Scarfe, L., Jinks, E., Lecky, D. A. J., Gudgeon, N. H., McQuade, R., Ono, M., Barthel, M., Hardt, W., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00159-2 · Cited by 19

Metabolic and epigenetic orchestration of (CAR) T cell fate and function

Akbari, B., Hosseini, Z., Shahabinejad, P., Ghassemi, S., Mirzaei, H. R., & O’Connor, R. S. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215948 · Cited by 20

EZH2: Its regulation and roles in immune disturbance of SLE

Yang, Y., Liu, K., Liu, M., Zhang, H., & Guo, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1002741 · Cited by 19

PYCR1 regulates glutamine metabolism to construct an immunosuppressive microenvironment for the progression of clear cell renal cell carcinoma.

Wei, X., Zhang, X., Wang, S., Wang, Y., Ji, C., Yao, L., & Song, N. (2022) · PubMed Central · Cited by 18

MHC Class II is Induced by IFNγ and Follows Three Distinct Patterns of Expression in Colorectal Cancer Organoids

Pickles, O. J., Wanigasooriya, K., Ptasinska, A., Patel, A. J., Robbins, H. L., Bryer, C., Whalley, C., Tee, L. J., Lal, N., Pinna, C. M. A., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0091 · Cited by 18

XGSEA: CROSS-species gene set enrichment analysis via domain adaptation

Cai, M., Nguyen, C. H., Mamitsuka, H., & Li, L. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa406 · Cited by 16

Temporal and Epigenetic Control of Plasticity and Fate Decision during CD8+T-Cell Memory DifferentiationPreprint

Pace, L. (2021) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a037754 · Cited by 19

Impact of tumor microenvironment on adoptive T cell transfer activity

Martín-Otal, C., Navarro, F. C., Casares, N., Lasarte-Cía, A., Sánchez-Moreno, I., Hervás‐Stubbs, S., Lozano, T., & Lasarte, J. J. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.03.002 · Cited by 18

Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effects

Huang, R., Wu, Y., & Zou, Z. (2022) · Epigenomics · doi:10.2217/epi-2022-0320 · Cited by 17

Increased expression of EZH2 indicates aggressive potential of urothelial carcinoma of the bladder in a Chinese population

Zhou, X., Liu, N., Zhang, J., Ji, H., Liu, Y., Yang, J., & Chen, Z. (2018) · Scientific Reports · doi:10.1038/s41598-018-36164-y · Cited by 17

Sindbis Virus with Anti-OX40 Overcomes the Immunosuppressive Tumor Microenvironment of Low-Immunogenic Tumors

Scherwitzl, I., Opp, S., Hurtado, A. M., Pampeno, C., Loomis, C. A., Kannan, K. S., Yu, M., & Meruelo, D. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.04.012 · Cited by 19

Emerging role of EZH2 in rheumatic diseases: A comprehensive review

Xu, W., Huang, Q., & Huang, A. (2022) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.14416 · Cited by 16

The pleiotropic roles of EZH2 in T-cell immunity and immunotherapy

Wang, Y., Bui, T., & Zhang, Y. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03466-x · Cited by 17

Identification of inhibitors of myeloid-derived suppressor cells activity through phenotypic chemical screening

Schröder, M., Loos, S., Naumann, S. K., Bachran, C., Krötschel, M., Umansky, V., Helming, L., & Swee, L. K. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1258503 · Cited by 16

MicroRNA‐181a restricts human γδ T cell differentiation by targeting Map3k2 and Notch2

Gordino, G., Costa-Pereira, S., Corredeira, P., Alves, P., Costa, L., Gomes, A. Q., Silva‐Santos, B., & Ribot, J. C. (2021) · EMBO Reports · doi:10.15252/embr.202052234 · Cited by 16

Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study

Chiang, N.-J., Tan, K. T., Bai, L., Hsiao, C., Huang, C., Hung, Y., Huang, C., Chen, S., Shan, Y., Chao, Y., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1152 · Cited by 16

Emerging roles of microRNAs in the metabolic control of immune cells

Yao, Q., Song, Z., Wang, B., & Zhang, J. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.06.024 · Cited by 17

The regulation of NDRG2 expression during ATLL development after HTLV-1 infection

Ichikawa, T., Nakahata, S., Fujii, M., Iha, H., Shimoda, K., & Morishita, K. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.07.001 · Cited by 15

Metabolic changes and interaction of tumor cell, myeloid-derived suppressor cell and T cell in hypoxic microenvironment

Ou, X., & Lv, W. (2020) · Future Oncology · doi:10.2217/fon-2019-0692 · Cited by 15

Metabolic interventions: A new insight into the cancer immunotherapy

Yu, T., Dong, T., Eyvani, H., Fang, Y., Wang, X., Zhang, X., & Lu, X. (2020) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2020.108659 · Cited by 16

Inhibition of histone methyltransferase EZH2 ameliorates early acute renal allograft rejection in rats

Li, L., Zhang, Y., Xu, M., Rong, R., Wang, J., & Zhu, T. (2016) · BMC Immunology · doi:10.1186/s12865-016-0179-3 · Cited by 15

Immunometabolic Targets in CD8+ T Cells within the Tumor Microenvironment of Hepatocellular Carcinoma

Lin, Y., Ruze, R., Zhang, R., Tuergan, T., Wang, M., Tulahong, A., Zhu, D., Yuan, Z., Jiang, T., Aji, T., et al. (2024) · Liver Cancer · doi:10.1159/000542578 · Cited by 17

EZH1/2 Inhibitors Favor ILC3 Development from Human HSPC-CD34+ Cells

Damele, L., Amaro, A. A., Serio, A., Luchetti, S., Pfeffer, U., Mingari, M. C., & Vitale, C. (2021) · Cancers · doi:10.3390/cancers13020319 · Cited by 14

A miRNA-mediated attenuation of hepatocarcinogenesis in both hepatocytes and Kupffer cells

Tian, Y., Zhang, M., Fan, M., Xu, H., Wu, S., Zou, S., Wang, Y., Tang, D., Zhang, C., Han, W., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.08.036 · Cited by 14

Epigenetic orchestration of cancer-immune dynamics: mechanisms, technologies, and clinical advancements

Lu, Y., Ma, S., Chan, Y.-T., Wu, Y., Feng, Y., & Wang, N. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.08.057 · Cited by 15

Lupus nephritis: The regulatory interplay between epigenetic and MicroRNAs

Xu, N., Liu, J., & Li, X. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.925416 · Cited by 13

Hurdle or thruster: Glucose metabolism of T cells in anti-tumour immunity

Zhang, S., Zhang, X., Yang, H., Liang, T., & Bai, X. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189022 · Cited by 14

A microRNA-regulated transcriptional state defines intratumoral CD8+ T cells that respond to immunotherapy

Tang, W. W., Battistone, B., Bauer, K. M., Weis, A. M., Barba, C., Fadlullah, M. Z. H., Ghazaryan, A., Tran, V. B., Lee, S.-H., Agir, Z. B., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115301 · Cited by 16

Emerging Landscapes of Tumor Immunity and Metabolism

Wu, F., Cheng, Y., Wu, L., Zhang, W., Zheng, W., Wang, Q., Cao, H., Pan, X., & Tang, W. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.575037 · Cited by 13

CHAC1 blockade suppresses progression of lung adenocarcinoma by interfering with glucose metabolism via hijacking PKM2 nuclear translocation

Pan, J., Wu, S., Pan, Q., Zhang, Y., Liu, H., Yao, Q., Chen, J.-Y., Li, J., & Xu, Y. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07114-6 · Cited by 12

Circadian immunometabolism: A future insight for targeted therapy in cancer

Tomar, M. S., Mohit, Kumar, A., & Shrivastava, A. (2024) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2024.102031 · Cited by 14

Overcoming immune suppression with epigenetic modification in ovarian cancer

McCaw, T. R., Randall, T. D., & Arend, R. C. (2018) · Translational research · doi:10.1016/j.trsl.2018.06.003 · Cited by 12

Histone Modifications as Biomarkers for Immunotherapy

Taylor, E. M., Koss, B. S., Davis, L. E., & Tackett, A. J. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9773-2_10 · Cited by 12

Targeting Glutamine Metabolism Transporter SLC25A22 Enhances CD8+ T‐Cell Function and Anti‐PD‐1 Therapy Efficacy in Cervical Squamous Cell Carcinoma: Integrated Metabolomics, Transcriptomics and T‐Cell‐Incorporated Tumor Organoid Studies

Ren, T., Qiu, J., Chen, F., Jiang, Q., Liu, Q., Wu, T., Jiang, H., & Hua, K. (2025) · Advanced Science · doi:10.1002/advs.202502225 · Cited by 11

Glycolysis-associated lncRNAs in cancer energy metabolism and immune microenvironment: a magic key

Zhang, X., Zhang, Y., Liu, Q., Zeng, A., & Song, L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1456636 · Cited by 11

Exploiting immunometabolism and T cell function for solid organ transplantation

Allocco, J., & Alegre, M. (2020) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104068 · Cited by 11

Epigenetic regulation of cancer stem cells: Shedding light on the refractory/relapsed cancers

Xu, L., Zhang, J., Sun, J., Hou, K., Yang, C., Guo, Y., Liu, X., Kalvakolanu, D. V., Zhang, L., & Guo, B. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115110 · Cited by 11

Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey–Holden Prostate Cancer Academy Meeting

Miyahira, A. K., Roychowdhury, S., Goswami, S., Ippolito, J. E., Priceman, S. J., Pritchard, C. C., Sfanos, K. S., Subudhi, S. K., Simons, J. W., Pienta, K. J., et al. (2016) · The Prostate · doi:10.1002/pros.23260 · Cited by 11

T‐cell exhaustion from a multiomics perspective: Differentiation mechanisms and regulatory networks in the journey from progenitor‐Exhausted T cells to terminally exhausted T cells

Zhu, T., Teng, X., Jiao, Q., Ren, Y., Wang, Y., & Feng, M. (2026) · Clinical and Translational Medicine · doi:10.1002/ctm2.70609 · Cited by 12

MicroRNA-mediated metabolic regulation of immune cells in cancer: an updated review

Khameneh, S. C., Razi, S., Lashanizadegan, R., Akbari, S., Sayaf, M., Haghani, K., & Bakhtiyari, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1424909 · Cited by 10

Lysine methylation modifications in tumor immunomodulation and immunotherapy: regulatory mechanisms and perspectives

Luo, Y., Lu, J., Lei, Z., Zhu, H., Rao, D., Wang, T., Fu, C., Zhang, Z., Xia, L., & Huang, W. (2024) · Biomarker Research · doi:10.1186/s40364-024-00621-w · Cited by 12

HMOX1: A pivotal regulator of prognosis and immune dynamics in ovarian cancer

Huang, J., & Tan, R. (2024) · BMC Women s Health · doi:10.1186/s12905-024-03309-3 · Cited by 10

The influence of fatty acid metabolism on T cell function in lung cancer

Petiti, J., Arpinati, L., Menga, A., & Carrà, G. (2025) · FEBS Journal · doi:10.1111/febs.70081 · Cited by 13

ASIATIC ACID INFLUENCES GLUCOSE HOMEOSTASIS IN P. BERGHEI MURINE MALARIA INFECTED SPRAGUE-DAWLEY RATS

Mavondo, G. A., Mkhwanazi, B. N., Mabandla, M. V., & Musabayane, C. T. (2016) · African Journal of Traditional Complementary and Alternative Medicines · doi:10.21010/ajtcam.v13i5.13 · Cited by 10

Identification of cell senescence molecular subtypes in prediction of the prognosis and immunotherapy of hepatitis B virus-related hepatocellular carcinoma

Xue, Y., Chen, P., Yi, W., Ruan, W., & Xiong, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1029872 · Cited by 10

Updates on altered signaling pathways in tumor drug resistance

Li, X., Huang, X. Y., Chang, M., Lin, R., Zhang, J., & Lü, Y. (2024) · Visualized Cancer Medicine · doi:10.1051/vcm/2024007 · Cited by 9

Alteration of the tumor microenvironment by pharmacological inhibition of EZH2 in hepatocellular carcinoma

Qiang, N., Ao, J., Nakamura, M., Chiba, T., Kusakabe, Y., Kaneko, T., Kurosugi, A., Kogure, T., Ma, Y., Zhang, J., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110068 · Cited by 11

The histone demethylase Utx controls CD8 + T‐cell‐dependent antitumor immunity via epigenetic regulation of the effector function

Noda, H., Suzuki, J., Matsuoka, Y., Matsumoto, A., Kuwahara, M., Kamei, Y., Takada, Y., & Yamashita, M. (2023) · Cancer Science · doi:10.1111/cas.15814 · Cited by 8

NOTCH Pathway Genes in Ovarian Cancer: Clinical Significance and Associations with Immune Cell Infiltration

Chen, B., Jiang, K., Wang, H., Lu, M., Lin, X., Chen, Q., Li, J., & Lu, X. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2809220 · Cited by 10

Advances in ovarian tumor stem cells and therapy

Chen, B., & Liu, J. (2024) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-024-01385-8 · Cited by 9

miRNA‑101‑3p.1 as an independent diagnostic biomarker aggravates chronic obstructive pulmonary disease via activation of the EGFR/PI3K/AKT signaling pathway

Chen, S., Zhang, Z., Chen, L., & Zhang, J. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10657 · Cited by 9

Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction (TUM9P.1007)

Zhao, E., Maj, T., Kryczek, I., Wei, S., Crespo, J., Wan, S., Vatan, L., Szeliga, W., Chinnaiyan, A. M., Welling, T. H., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.194.supp.210.9 · Cited by 1

Glycolysis and EZH2 boost T cell weaponry against tumors

Bantug, G. R., & Hess, C. (2015) · Nature Immunology · doi:10.1038/ni.3346 · Cited by 4

Abstract 1029: Epigenetic control of tumor-infiltrating lymphocyte metabolic-exhaustion

Koss, B. S., Shields, B. D., Taylor, E. M., Storey, A. J., Byrum, S. D., Gies, A. J., Washam, C. L., Choudhury, S. R., Ahn, J. H., Uryu, H., et al. (2020) · Cancer Research · doi:10.1158/1538-7445.am2020-1029

Tumor-mediated suppression of T cells is EZ(H2)

Foley, J. F. (2016) · Science Signaling · doi:10.1126/scisignal.aaf2209

Abstract SY17-01: Metabolic impact on immune cell subsets in the tumor microenvironment and its therapeutic relevance

Zou, W. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-sy17-01 · Cited by 1